ADAP - Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript

Adaptimmune Therapeutics plc (ADAP) Q3 2020 Earnings Conference Call November 5, 2020 08:30 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business Officer Conference Call Participants Tony Butler - ROTH Capital David Ruch - SVB Leerink Gabriel Fung - Mizuho Securities Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to Adaptimmune's Third Quarter 2020 Financial Results and Business Update. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions] I would now like to hand the conference over to your host, Adaptimmune's Investor Relations, Juli Miller. Madam, please go ahead. Juli Miller Good morning and welcome to Adaptimmune's conference call to discuss our third quarter 2020 financial results and business update. I

For further details see:

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript